Centurion Wealth Management LLC Makes New $214,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Centurion Wealth Management LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, Holdings Channel.com reports. The firm acquired 1,601 shares of the life sciences company’s stock, valued at approximately $214,000.

Several other large investors have also made changes to their positions in ILMN. Golden State Wealth Management LLC purchased a new stake in Illumina in the 4th quarter worth $32,000. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina during the fourth quarter worth about $45,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 1.8 %

Shares of ILMN opened at $85.60 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $13.56 billion, a P/E ratio of -11.15, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company’s 50-day moving average price is $113.52 and its 200 day moving average price is $129.86. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Guggenheim cut their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reduced their price objective on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Stephens restated an “overweight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Barclays reaffirmed an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Finally, Robert W. Baird decreased their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.